TD Cowen raised the firm’s price target on Thermo Fisher (TMO) to $654 from $612 and keeps a Buy rating on the shares. The firm said 3Q looked good with 5% EPS beat, organic roughly 0.5% better and the 2025 guide was raised (organic intact). Biopharma is the strongest market (MSD% 3Q growth) and getting stronger (biotech, PPD), supporting a better 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMO:
- Thermo Fisher price target raised to $590 from $500 at UBS
- Thermo Fisher’s Mixed Financial Outlook: Hold Rating Amid Growth Challenges and Positive Adjustments
- Thermo Fisher price target raised to $620 from $530 at Deutsche Bank
- Thermo Fisher price target raised to $580 from $500 at Citi
- Thermo Fisher price target raised to $625 from $585 at Barclays